Profile data is unavailable for this security.
About the company
Hansoh Pharmaceutical Group Company Ltd is an investment holding company primarily engaged in the research and development, production and sale of a series of pharmaceutical products. The Company’s innovative drug products include Ameile, Hansoh Xinfu, Mailingda, Fulaimei, Hengmu, XINYUE, Saint Luolai and other products. The Company’s drug products are mainly used in oncology, anti-infective diseases, central nervous system (CNS) diseases, metabolic diseases and other therapeutic areas. The Company mainly conducts its business in the domestic market.
- Revenue in HKD (TTM)13.29bn
- Net income in HKD5.18bn
- Incorporated2015
- Employees9.10k
- LocationHansoh Pharmaceutical Group Company Ltd287 Xiangke Road, Pudong New DistrictSHANGHAI 201210ChinaCHN
- Websitehttp://www.hspharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Pharmaceutical Group Ltd | 275.32bn | 4.15bn | 30.54bn | 72.76k | 7.36 | 0.5746 | 2.40 | 0.1109 | 0.6603 | 0.6603 | 43.82 | 8.46 | 0.966 | 6.09 | 3.00 | 3,772,212.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| CSPC Pharmaceutical Group Ltd | 34.78bn | 6.51bn | 55.15bn | 20.30k | 8.46 | 1.44 | 13.95 | 1.59 | 0.5497 | 0.5497 | 2.94 | 3.22 | 0.6914 | 3.01 | 5.24 | 1,480,137.00 | 13.25 | 16.08 | 17.64 | 21.57 | 71.38 | 72.95 | 19.16 | 19.63 | 2.22 | 84.54 | 0.0106 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
| Sino Biopharmaceutical Ltd | 29.45bn | 2.20bn | 61.64bn | 24.44k | 27.53 | 1.67 | 9.69 | 2.09 | 0.1192 | 0.2439 | 1.60 | 1.97 | 0.4050 | 2.37 | 3.74 | 1,141,047.00 | 7.42 | 13.11 | 14.50 | 21.74 | 82.92 | 80.37 | 18.33 | 27.47 | 1.07 | 11.10 | 0.1868 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| Innovent Biologics Inc | 8.19bn | -1.41bn | 71.44bn | 5.26k | -- | 5.22 | -- | 8.72 | -0.8824 | -0.8824 | 5.11 | 8.39 | 0.3905 | 1.32 | 6.25 | 1,681,855.00 | -6.71 | -13.06 | -8.22 | -15.85 | 82.44 | 84.51 | -17.18 | -43.44 | 2.51 | -3.68 | 0.2123 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
| Hansoh Pharmaceutical Group Company Ltd | 13.29bn | 5.18bn | 119.01bn | 9.10k | 23.25 | 3.88 | 21.18 | 8.95 | 0.8622 | 0.8622 | 2.21 | 5.17 | 0.3804 | 1.80 | 3.87 | 1,457,205.00 | 14.82 | 11.58 | 17.87 | 13.98 | 91.07 | 90.78 | 38.97 | 29.28 | 7.81 | -- | 0.0043 | 12.75 | 7.69 | 5.52 | 26.85 | 11.49 | -10.45 | -- |
Data as of Sep 19 2024. Currency figures normalised to Hansoh Pharmaceutical Group Company Ltd's reporting currency: Hong Kong Dollar HKD
5.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Jul 2024 | 97.88m | 1.65% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 36.09m | 0.61% |
| E Fund Management Co., Ltd.as of 30 Jun 2024 | 31.51m | 0.53% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 30 Jun 2024 | 28.90m | 0.49% |
| FIL Investment Management (Hong Kong) Ltd.as of 31 Jul 2024 | 28.26m | 0.48% |
| Strategic Advisers LLCas of 31 Jul 2024 | 27.63m | 0.47% |
| UBS Asset Management (Hong Kong) Ltd.as of 31 Jul 2024 | 25.82m | 0.44% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 23.75m | 0.40% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 20.01m | 0.34% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 17.24m | 0.29% |
More ▼
Data from 31 Dec 2023 - 12 Sep 2024Source: FactSet Research Systems Inc.
